Reprint

Drug Metabolism/Transport and Pharmacokinetics

Edited by
December 2021
252 pages
  • ISBN978-3-0365-2459-7 (Hardback)
  • ISBN978-3-0365-2458-0 (PDF)

This book is a reprint of the Special Issue Drug Metabolism/Transport and Pharmacokinetics that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

This book serves to highlight the pharmacokinetics/drug–drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic drugs as well as natural herbal medicines. It also covers the pharmacokinetic interactions caused by inhibiting or inducing the metabolic or transport activities under disease states or the coadministration of potential inhibitors. It also deals with microenvironmental pharmacokinetic profiles as well as population pharmacokinetics, which gives new insights regarding the pharmacokinetic features with regard to drug metabolism and transporters.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
tofacitinib; dose-dependent pharmacokinetics; hepatic and intestinal first-pass effect; rats; catalposide; in vitro human metabolism; UDP-glucuronosyltransferase; sulfotransferase; carboxylesterase; celecoxib; drug–drug interaction; fluorescence; HPLC; metabolism; repaglinide; HSG4112; anti-obesity agent; stereoselectivity; pharmacokinetics; compound K; protopanaxadiol (PPD); pharmacokinetics; biliary excretion; intestinal metabolism; Carthamus tinctorius extract; notoginseng total saponins; comparative pharmacokinetic study; large volume direct injection; compatibility mechanism; mertansine; human hepatocytes; cytochrome P450; UDP-glucuronosyltransferases; drug–drug interaction; sodium-glucose cotransporter 2 (SGLT2) inhibitors; DWP16001; kidney distribution; inhibition mode; diabetes; transporter-enzyme interplay; influx transporter; efflux transporter; physiologically based pharmacokinetic model; pharmacokinetics; cytochrome P450 enzymes; tiropramide; healthy Korean subjects; modeling; population pharmacokinetic; quercetin; breast cancer resistance protein; inhibitor; prazosin; sulfasalazine; kinetic analysis; pharmacokinetics; food–drug interactions; Caco-2; EpiIntestinal; first-pass; P-gp; BCRP; drug transporter; CYP3A4; UDP-glucuronosyltransferase; carboxylesterase; oral availability; automatization; drug absorption; drug dosing; head-and-neck cancer; pharmacokinetics; real-time measurements; taxanes; tissue engineering; UHPLC-MS/MS; metformin; verapamil; drug interaction; organic cation transporter 2; renal excretion; tofacitinib; acute renal failure; gentamicin; cisplatin; pharmacokinetics; hepatic CYP3A1(23); creatinine clearance; renal clearance; nonrenal clearance